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Abstract
Background: A simple, specific, and fast stability indicating reverse phase liquid chromatographic method
was established for instantaneous determination of moxifloxacin and prednisolone in bulk drugs and
pharmaceutical formulations.
Results: Optimum chromatographic separations among the moxifloxacin, prednisolone and stress-induced
degradation products were achieved within 10 minutes by use of BDS Hypersil C8 column (250 X 4.6 mm, 5 μm)
as stationary phase with mobile phase consisted of a mixture of phosphate buffer (18 mM) containing 0.1% (v/v)
triethylamine, at pH 2.8 (adjusted with dilute phosphoric acid) and methanol (38:62 v/v) at a flow rate of 1.5 mL
min-1. Detection was performed at 254 nm using diode array detector. The method was validated in accordance
with ICH guidelines. Response was a linear function of concentrations over the range of 20–80 μg mL-1 for
moxifloxacin (r2 ≥ 0.998) and 40–160 μg mL-1 for prednisolone (r2 ≥ 0.998). The method was resulted in good
separation of both the analytes and degradation products with acceptable tailing and resolution. The peak purity
index for both the analytes after all types of stress conditions was ≥ 0.9999 indicated a complete separation of
both the analyte peaks from degradation products. The method can therefore, be regarded as stabilityindicating.
Conclusions: The developed method can be applied successfully for simultaneous determination of moxifloxacin
and prednisolone in pharmaceutical formulations and their stability studies.
Keywords: Reverse phase liquid chromatography, Moxifloxacin, Prednisolone, Degradation products, ICH guidelines
etc
Introduction
Moxifloxacin hydrochloride is chemically designated as
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-
octahydro-6 H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quino-
linecarboxylic acid hydrochloride [Figure 1]. It is a
broad-spectrum antibiotic that functions by inhibiting
DNA gyrase, a type II topoisomerase, and topoisomerase
IV enzymes [1] necessary to separate bacterial DNA,
thereby inhibiting cell replication. It is used for bacterial
conjunctivitis, keratitis, pre & post operative conditions to
control the infections of the eyes. Prednisolone acetate
[Figure 1] chemically designated as 11β 17, 21-trihydroxy-
pregna-1,4-diene-3,20-dione 21-acetate is a corticosteroid,
used principally for steroid-responsive inflammatory ocu-
lar conditions for which a corticosteroid is indicated and
where bacterial ocular infection or a risk of infection
exists [2]. Both moxifloxacin and prednisolone have been
analysed by various techniques either alone or in combin-
ation with other drugs. The analytical methods existed for
moxifloxacin hydrochloride included determination by
spectrophotometry [3-5], and high performance liquid
chromatography [6,7]. The analytical methods existed for
prednisolone included determination by micellar electro-
kinetic chromatography [8], spectrophotometry [9], high
performance liquid chromatography [10,11], and thin
layer chromatography densitometry [12].
The combination of moxifloxacin and prednisolone
has not been adopted by any official pharmacopoeia
(USP, BP or EP etc.). An extensive review of the litera-
ture did not revealed any stability indicating HPLC
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method for simultaneous determination of both drugs.
Therefore, attempts were made to develop and validate
simple, precise, and sensitive, isocratic reverse phase sta-
bility indicating high performance liquid chromato-
graphic method for simultaneous determination of both
drugs and their degradation products in pharmaceutical
formulations. We are currently engaged in binary com-
bination analysis of different classes of drugs in pharma-
ceutical formulations and in human plasma [13-23].
Experimental
Chemicals and reagents
Reference standards of moxifloxacin hydrochloride and
Prednisolone acetate with stated purity of 99.97 and
99.46% respectively were obtained from Schazoo Zaka
Laboratories (Lahore, Pakistan). Occumox P and Mof-
trex P eye drops (claimed to contain 5 mg per mL of
moxifloxacin and 10 mg per mL of prednisolone) were
used in this study. Occumox P eye drops contains
0.02% w/v benzalkonium chloride as preservative in ster-
ile aqueous base and Moftrex P eye drops contains
0.25% w/v hydroxypropylmethylcellulose (HPMC) as
preservative in the sterile aqueous base. Methanol
(HPLC grade), potassium dihydrogen phosphate, phos-
phoric acid, triethylamine, sodium hydroxide, hydro-
chloric acid and hydrogen peroxide (analytical reagent
grade) were from M.S Traders Lahore, Pakistan (Fluka
origin). Double distilled water was used throughout the
analysis. Mobile phase was filtered using 0.45μm nylon
filters by Millipore (USA).
Equipment and chromatographic conditions
The HPLC system consisted of Shimadzu LC-20A sys-
tem (Kyoto, Japan) equipped with model LC-20AT
pump, SPD-M20A Diode array detector (set at 254 nm),
and DGU-20A5 online degasser, and a Rheodyne injec-
tion valve with a 20 μL loop. Peak areas were integrated
using a Shimadzu LC solution (version 1.227) software
program. The experimental conditions were optimized
on a BDS Hypersil C8 column (250 X 4.6 mm, 5 μm) at
room temperature. Mobile phase consisted of methanol
and 18 mM phosphate buffer (pH 2.8) in the ratio of
(62:38 v/v, respectively). The phosphate buffer was
prepared by taking 2.448 g of potassium dihydrogen
phosphate in 1000 mL of water. Triethylamine (1 mL)
was added to it and pH was then adjusted to 2.8 using
phosphoric acid. Flow rate of the mobile phase was
1.5 mL min-1 and all chromatographic experiments were
performed at room temperature (25°C ± 2°C).
Preparation of standard stock solution
Stock solution was prepared to reduce the number of re-
petitive operations involved and hence, the chances of
human or experimental error. Moreover direct weighing
of moxifloxacin (50 μg mL-1) and prednisolone
(100 μg mL-1) to prepare the working standard solution
cannot be performed with sufficient accuracy. Standard
stock solution of moxifloxacin (1250 μg mL-1) and pred-
nisolone (2500 μg mL-1) was prepared by accurately
weighing 31.25 mg moxifloxacin and 62.5 mg prednisol-
one dissolved in 5–7 mL methanol in 25 mL volumetric
flask and then up to the mark with mobile phase. The
stock solution was used to prepare the working standard
solution of moxifloxacin and prednisolone. Stock solu-
tion of moxifloxacin and prednisolone was also used to
prepare working solutions for accuracy, precision, linear-
ity (0.4 mL-1.6 mL of the stock solution diluted to
25 mL with mobile phase), forced degradation studies
(1 mL of stock solution + 1 mL of acid or base solution
diluted to 25 mL with mobile phase) and robustness etc.
Preparation of standard solution
1 mL of the standard stock solution was diluted to 25 mL
with mobile phase to prepare working standard solution
having concentration equal to 50 μg mL-1 of moxifloxacin
and 100 μg mL-1 of prednisolone. The solution was
filtered through 0.45μm nylon filter before analysis.
Preparation of sample solution
1 mL commercial eye drops (composition 5 mg mL-1
moxifloxacin and 10 mg mL-1 prednisolone) were
diluted to 100 mL with mobile phase to obtain concen-
tration equal to 50 μg mL-1 of moxifloxacin and
100 μg mL-1 of prednisolone. The solution was filtered
through 0.45 μm nylon filter before analysis.
Figure 1 Chemical Structures of Moxifloxacin HCl (A) and Prednisolone Acetate (B).
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Linearity
Linear calibration plots of the proposed method were
obtained over concentration ranges of 20–80 μg mL-1
(20, 30, 40, 50, 60, 70 and 80 μg mL-1) for moxifloxacin
and 40–160 μg mL-1 prednisolone (40, 60, 80, 100, 120,
140 and 160 μg mL-1). Each solution was prepared
in triplicate.
Accuracy
Accuracy of an analytical procedure is the closeness of
agreement between accepted conventional true values
(reference values) and the values found. Accuracy of the
developed method was determined by two ways i) stand-
ard addition method and ii) analysis of synthetic mix-
tures of moxifloxacin and prednisolone eye drops. In
the standard addition method known quantities (50, 100
and 150%) of moxifloxacin and prednisolone were sup-
plemented to the sample solution previously analysed
and then experimental and true values were compared.
In the synthetic mixture method known quantities (50,
100 and 150%) of moxifloxacin and prednisolone of
known purity have been spiked to the placebo compo-
nents (benzalkonium chloride and sodium chloride in
aqueous base). Synthetic mixture (100% nominal analyt-
ical concentration) of moxifloxacin (50 μg mL-1) and
prednisolone (100 μg mL-1) was prepared by mixing
moxifloxacin (500 mg), prednisolone (1000 mg), ben-
zalkonium chloride (0.02 g) as preservative and sodium
chloride (0.3 g) in 100 ml of purified water for 30 min-
utes using magnetic stirrer. Three levels of synthetic
mixtures were prepared corresponding to 50, 100 and
150% of nominal analytical concentration (50 μg mL-1
of moxifloxacin and 100 μg mL-1 of prednisolone) and
analysed by the developed method.
Precision
Repeatability was studied by determination of intra-day
and inter-day precision. Intra-day precision was deter-
mined by injecting five standard solutions of three dif-
ferent concentrations on the same day and inter-day
precision was determined by injecting the same solu-
tions for three consecutive days. Relative standard devi-
ation (RSD%) of the peak area was then calculated to
represent precision.
Specificity (stress testing)
Stress testing was carried out using different ICH pre-
scribed stress conditions such as acidic, basic, oxidative,
thermal and photolytic stresses. All stress studies were
performed in 25 mL volumetric flask.
Acid degradation studies
Acid degradation study was performed in versatile envi-
ronmental test chamber (Sanyo, Japan) at 40°C/75% RH
using 5 M HCl. For this purpose, 1 mL of the standard
stock solution was taken in 25 mL volumetric flask. One
milliliter of 5 M HCl was added in the flask and kept in
versatile environmental test chamber at 40°C/75% RH
for 16 h. After completion of the stress the solution
was neutralized by using 5 M NaOH and completed up
to the mark with mobile phase.
Base degradation studies
Base degradation study was performed at 22°C/58% RH
using 5 M NaOH. For this purpose, 1 mL of the stand-
ard stock solution was taken in 25 mL volumetric flask.
One milliliter of 5 M NaOH was added in the flask and
kept at 22°C/58% RH for forty minutes. After
completion of the stress the solution was neutralized
by using 5 M HCl and completed up to the mark with
mobile phase.
Oxidative degradation studies
Oxidative degradation study was performed in versatile
environmental test chamber (Sanyo, Japan) at 40°C/75%
RH using 6% H2O2. For this purpose, 1 mL of the stand-
ard stock solution was taken in 25 mL volumetric
flask. One milliliter of 6% H2O2 was added in the
flask and kept in versatile environmental test chamber at
40°C/75% RH for 16 h. After completion of the stress,
the 25 mL flask was completed up to the mark with
mobile phase.
Thermal degradation studies
Thermal degradation studies were performed at two dif-
ferent temperatures i) in versatile environmental test
chamber (Sanyo, Japan) at 40°C/75% RH and ii) in oven
(Gallenkamp, UK) at 105°C (dry heat thermolysis). For
this purpose, 1 mL of the standard stock solution was
taken in two different 25 mL volumetric flasks and kept
in versatile environmental test chamber at 40°C/75% RH
for 144 h and 288 h. After specified time, the 25 mL
flasks were completed up to the mark with mobile
phase. For dry heat thermolysis, 62.5 mg moxifloxacin
and 125 mg of prednisolone were mixed for 30 minutes
in glass petty dish with spatula and placed in oven at
105°C for seven hours. After specified time, 5–7 mL
methanol was added to the powder mixture and up to
mark 50 mL with mobile phase. 1 mL of this solution
was further diluted to 25 mL with mobile phase.
Photolytic degradation studies
For photolytic degradation study 1 mL of the standard
stock solution was taken in 25 mL volumetric flask
placed in the direct sunlight for 1 h. After completion of
the stress the 25 mL flask was completed up to the mark
with mobile phase.
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Robustness
Premeditate variations were performed in the experimental
conditions of the proposed method to assess the method
robustness. For this intention, minor changes were made
in mobile phase composition, flow rate and pH of buffer
solution. The effect of these changes on chromatographic
parameters such as retention time, tailing factor and
number of theoretical plates was then measured.
Limit of detection and limit of quantitation
Limit of quantitation and limit of detection values were
determined by the signal-to-noise (S/N) approach. Limit













Moxifloxacin 4521 1.17 +++
Prednisolone 0.92 6568 1.01 13.66 +++
Methanol: Phosphate Buffer
pH 3.5 (62:38)
Moxifloxacin 4251 1.29 +++
Prednisolone 0.84 5784 1.18 12.24 +++
Methanol: Phosphate Buffer
pH 4.5 (62:38)
Moxifloxacin 4122 1.47 +++
Prednisolone 0.54 5541 1.14 9.45 —
Methanol: Phosphate Buffer
pH 6.5 (62:38)
Moxifloxacin 3801 1.40 +++
Prednisolone 0.41 4787 1.28 11.87 —
Chromatographic conditions, mobile phase methanol: 0.018 M phosphate buffer 62:38, pH 2.8, or 3.5, or 4.5, or 6.5, Column BDS Hypersil C8 (250 X 4.6, 5 μm),
flow rate 1.5 mL min-1,
injection volume 20 μL, wavelength 254 nm, +++ is peak acceptable and — is peak not acceptable.
Figure 2 Chromatogram of moxifloxacin and prednisolone in pharmaceutical formulations.
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of quantitation is the concentration of the analyte that
give a signal-to-noise (S/N) ratio of 10:1 at which analyte
can be readily quantified with accuracy and precision.
Limit of detection is the concentration of the analyte
that give signal-to-noise (S/N) ratio of 3:1 at which ana-
lyte can be readily detected. To investigate the limit of
quantitation and limit of detection solutions of different
concentrations were prepared by spiking know amounts
of moxifloxacin and prednisolone into excipients (ben-
zalkonium chloride and sodium chloride). Each solution
was prepared according to the procedure and analysed
repeatedly to determine the S/N ratio. The average S/N
ratio from all the analyses at each concentration level
was used to calculate the limit of quantitation and limit
of detection. The concentration level that gives an S/N
ratio of about 10:1 at which analytes can be readily
quantified with accuracy and precision was reported as
the limit of quantitation. The concentration level that
gives an S/N ratio of about 3:1 at which analytes can be
readily detected was reported as the limit of detection.
Results and discussion
In reverse phase liquid chromatographic separation of
pharmaceutical drugs, choice of a stationary phase
depends on the chemical structures of the target ana-
lytes. Moxifloxacin and prednisolone drugs have high
carbon to heteroatom ratio and therefore can be sepa-
rated through C8 or C18 stationary phase based mainly
on their overall hydrophobicity. Due to the presence of
π electrons, moxifloxacin and prednisolone also con-
sidered to be separated using phenyl stationary phase
involving π- π interactions between the phenyl groups
in the stationary phase and any unsaturated bonds in
moxifloxacin and prednisolone structures. Both the
drugs also contains polar functional groups (−COOH or
–OH etc.) and may be separated using cyano stationary
phase involving dipole-dipole interactions.
In this work we proposed a simple, fast, and accurate
stability indicating RP-HPLC method for simultaneous
determination of moxifloxacin and prednisolone. For
optimization of the chromatographic conditions and
to obtain symmetrical peaks with better resolution and
with no peak impurity, various chromatographic condi-
tions such as composition of mobile phase, mobile
phases with different pH, stationary phases with different
packing materials (Hypersil BDS C8, Hypersil ODS C18,
Hypersil BDS Phenyl-2, and Hypersil BDS Cyano) and
configurations (10, 15, 25 cm columns) were applied to
moxifloxacin and prednisolone combination.
Optimization of mobile phase, stationary phase and pH
Method development process was initiated with different
ratios (20:80, 30:70, 40:60 and 50:50) of water and
methanol at different pH. With methanol and water
broad peaks of prednisolone and asymmetrical peaks of
moxifloxacin were obtained on all four different station-
ary phases (Hypersil BDS C8, Hypersil ODS C18, Hyper-
sil BDS Phenyl-2, and Hypersil BDS Cyano) with long




Standard addition Synthetic mixtures
Measured
concentration




(μg mL-1) ± SD;
RSD (%)
Moxifloxacin 25.0 25.2 ± 0.1; 0.1 24.8 ± 0.2; 0.3
50.0 50.4 ± 0.9; 1.4 50.6 ± 0.4; 0.6
75.0 76.8 ± 1.1; 1.7 74.8 ± 1.1; 1.2
Prednisolone 50.0 50.9 ± 0.7; 0.7 50.1 ± 0.9; 0.1
100.0 98.4 ± 0.9; 0.7 99.7 ± 0.8; 1.3
150.0 147.9 ± 0.7; 0.2 150.0 ± 0.5; 0.7
n=Average of 5 analysis, Chromatographic conditions: mobile phase
methanol: 18 mM phosphate buffer 62:38, v/v, pH 2.8, Column BDS Hypersil
C8 (250 X 4.6, 5 μm), flow rate 1.5 mL min-1, injection volume 20 μL,
wavelength 254 nm.












Moxifloxacin 25.0 24.8 ± 0.6; 1.7 25.3 ± 0.4; 1.1
50.0 50.5 ± 0.7; 0.2 51.2 ± 0.8; 1.0
75.0 74.1 ± 0.4; 1.5 75.7 ± 1.2; 1.5
Prednisolone 50.0 50.0 ± 0.1; 0.3 50.4 ± 1.7; 1.0
100.0 101.5 ± 0.4; 0.9 102.0 ± 0.9; 0.5
150.0 153.1 ± 0.8; 1.7 151.8 ± 0.7; 1.6
n=Average of 5 analysis, Chromatographic conditions: mobile phase
methanol: 18 mM phosphate buffer 62:38, v/v, pH 2.8, Column BDS Hypersil
C8 (250 X 4.6, 5 μm), flow rate 1.5 mL min-1, injection volume 20 μL,
wavelength 254 nm.
Table 4 Robustness study of moxifloxacin
Chromatographic
conditions
Assay % tR (min) Theoretical
plates
Tailing
Methanol:buffer (64:36) 99.1 3.241 4347 1.26
Methanol:buffer (62:38) 102.0 3.446 4328 1.26
Methanol:buffer (60:40) 100.5 3.615 4498 1.24
Flow rate (1.3 mL/min) 100.8 3.825 4448 1.26
Flow rate (1.5 mL/min) 98.4 3.447 4319 1.26
Flow rate (1.7 mL/min) 98.2 3.089 4358 1.26
Buffer (pH 2.6) 101.0 3.442 4348 1.24
Buffer (pH 2.8) 100.9 3.446 4442 1.26
Buffer (pH 3.0) 101.2 3.443 4488 1.24
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in the temperature of column oven to 50°C did not
improve peak tailing and broadening of analytes. The
peak tailing of moxifloxacin may be due to the chelate
formation of metal ion impurity of the stationary phases
with the carboxyl group of C-3 and oxygen atom of C-4
of moxifloxacin or it may be caused due to unwanted
interactions between nitrogen atoms (of moxifloxacin)
and silanol residues of stationary phases. The peak
broadening of prednisolone may be due to low polarity
of the mobile phase. Then polarity of the mobile phase
was increased by using phosphate buffer in the mobile
phase composition. Further chromatographic experiments
were performed on four different stationary phases
(Hypersil BDS C8, Hypersil ODS C18, Hypersil BDS
Phenyl-2, and Hypersil BDS Cyano) using methanol:
phosphate buffer as mobile phase along with (0.1%v/v)
triethylamine (as silanol blocker). Highly symmetrical
and sharp peaks of moxifloxacin and prednisolone were
obtained with methanol: 0.018 M phosphate buffer con-
taining 0.1%v/v triethylamine (62:38,v/v) on Hypersil BDS
C8 columns (with better resolution, capacity factor, peak
shapes and theoretical plates) as compared to other sta-
tionary phases (Hypersil ODS C18, Hypersil BDS Phenyl-
2, and Hypersil BDS Cyano). The variations in the com-
position of the mobile phase and dissimilar stationary
phases had substantial influences on peak shape, tailing
factor, retention factor, theoretical plates and resolution.
In order to optimize the appropriate pH of the phos-
phate buffer solution, chromatographic experiments
were performed at four different pH (2.8, 3.5, 4.5 and
6.5) values of the buffer solution. Mobile phase was pre-
pared in the ratio of methanol: phosphate buffer (62: 38,
v/v) containing 0.1%v/v triethylamine. Hypersil BDS C8
column was used as stationary phase to optimize the
appropriate pH. Highly symmetrical and sharp peaks of
moxifloxacin and prednisolone were obtained at pH 2.8
and 3.5 by using methanol: 0.018 M phosphate buffer
with better resolution, capacity factor, and theoretical
plates at pH 2.8 as compared to pH 3.5 [Table 1]. Finally,
methanol: phosphate buffer 0.018 M, pH 2.8 (62:38,v/v)
was selected which provided symmetrical peaks with
acceptable peak purity index of moxifloxacin and
prednisolone using Hypersil BDS C8 column. Under
the mentioned chromatographic conditions highly sym-
metrical and sharp peaks of moxifloxacin and prednisol-
one were obtained at retention times of 3.449, and
7.447 min, respectively [Figure 2].
The developed chromatographic method was valid-
ated using ICH guidelines [24]. Validation parameters
Table 5 Robustness Study of Prednisolone
Chromatographic
Conditions
Assay % tR (min) Theoretical
plates
Tailing
Methanol:buffer (64:36) 99.2 6.947 6328 1.01
Methanol:buffer (62:38) 100.8 7.447 6277 1.01
Methanol:buffer (60:40) 99.7 8.499 6341 1.01
Flow rate (1.3 mL/min) 99.4 8.433 6358 1.01
Flow rate (1.5 mL/min) 100.5 7.447 6249 1.02
Flow rate (1.7 mL/min) 100.4 6.569 6371 1.01
Buffer (pH 2.6) 100.4 7.497 6395 1.00
Buffer (pH 2.8) 99.9 7.447 6354 1.02
Buffer (pH 3.0) 98.8 7.498 6248 1.00
Figure 3 Chromatogram of moxifloxacin and prednisolone under acidic stress.
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included linearity, accuracy, precision, robustness, speci-
ficity, limit of detection and quantitation.
Linear calibration plots for the proposed method were
obtained in concentration ranges of 20–80 μg mL-1 (20,
30, 40, 50, 60, 70 and 80 μg mL-1) for moxifloxacin and
40–160 μg mL-1 prednisolone (40, 60, 80, 100, 120, 140
and 160 μg mL-1). The linear regression equation
(r2 ≥ 0.998) for moxifloxacin was found to be Y= 22711
X+ 23429 (Y = aX+ b) in which Y is the dependent
variable, X is independent variable, 22711 is slope
(denoted by a) which shows change in dependent (Y)
variable per unit change in independent (X) variable and
23429 (denoted by b) is the Y-intercept i.e., the value of
Y variable when X= 0. The linear regression equation
(r2 ≥ 0.999) for prednisolone was Y= 69932 X+ 73339
(Y = aX+ b) in which 69932 is the slope (a) and 73339 is
the Y-intercept (a point of the Y-coordinate where a
given line intersects the Y-axis) at which X is equal to
Figure 4 Chromatogram of moxifloxacin and prednisolone under basic stress.
Figure 5 Chromatogram of moxifloxacin and prednisolone under oxidative stress.
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zero. It defines the elevation of the line. The Y-intercept
provides with an estimate of the variability of the
method. For example, the ratio percent of the Y-
intercept with the variable data at nominal concentration
is used to estimate the method variability.
The limit of detection (LOD) and quantitation (LOQ)
were determined by making serials of dilutions. LOD
was found to be 0.088 μg mL-1 and 0.175 μg mL-1 for
moxifloxacin and prednisolone, respectively (signal to
noise ratio of 3:1). LOQ was found to be 0.284 μg mL-1
and 0.559 μg mL-1 for moxifloxacin and prednisolone,
respectively (signal to noise ratio of 10:1).
Accuracy of the developed method was performed by
the standard addition and synthetic mixture techniques.
Three levels of solutions (50, 100 and 150%) of the
nominal analytical concentrations were prepared and
Figure 6 Chromatogram of moxifloxacin and prednisolone under thermal stress.
Figure 7 Chromatogram of moxifloxacin and prednisolone under photolytic stress.
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analysed by the developed method. Percentage recover-
ies along with standard deviation and relative standard
deviations for each analyte are given in [Table 2]. Recov-
ery studies showed the method to be highly accurate
and suitable for intended use.
Intra-day precision was determined by injecting five
standard solutions of three different concentrations on
the same day and inter-day precision was determined by
injecting the same solutions for three consecutive days.
Relative standard deviation (RSD %) of the peak area
calculated to represent precision. The results of intra-
day and inter-day precision are presented in [Table 3].
Robustness of the method was performed by slightly
varying the chromatographic conditions. The results
showed that slight variations in chromatographic condi-
tions had negligible effect on the chromatographic para-
meters [Table 4 and Table 5].
Specificity of the developed method was evaluated by
applying different stress conditions (acid, base, oxidation,
thermal and photolytic) to moxifloxacin and prednisol-
one in combination form. The chromatograms under
different stress conditions are showed in [Figures 3, 4, 5,
6, 7]. The results of stress studies are given in [Table 6].
All the stress conditions applied were enough to
degrade both the drugs. Comparison of the two drugs
showed that moxifloxacin is more stable as compared to
prednisolone. Under acidic conditions prednisolone was
degraded up to 95.2% and moxifloxacin was degraded
up to 13.7%. Under basic stress prednisolone was
degraded up to 96.6% and moxifloxacin was found to be
stable under basic stress. Under oxidative stress prednis-
olone was degraded up to 11.7% and moxifloxacin was
found to be stable under oxidative stress. Under thermal
stress (dry heat) moxifloxacin was degraded up to 6.3%
and prednisolone was degraded up to 15.9%. Under
photolytic stress prednisolone and moxifloxacin were
degraded up to 5.5% and 11.5%, respectively. From these
stress studies it is thus concluded that prednisolone and
moxifloxacin drugs are not stable in basic, acidic, oxida-
tive, thermal and photolytic stress conditions.
In addition to the percentage degradation of each
drug, a number of degradation products (impurities)
were produced under acidic (6 impurity/degradation
peaks with IMP 3 as major degradation peak), basic
(6 impurity/degradation peaks with IMP 2 and IMP 3
as major degradation peaks), oxidative (6 impurity/
degradation peaks with IMP 1 as degradation peak) and
photolytic stress (7 impurity/degradation peaks with
IMP 5 as major degradation peak) conditions. The devel-
oped method effectively separated the degradation pro-
ducts or impurities (6 impurity peaks under acidic
stress, 6 impurity peaks under basic stress, 6 impurity
peaks under oxidative stress, 7 impurity peaks under
photolytic stress,) from analyte peaks [Figures 3, 4, 5, 6,
7]. Therefore, the developed method is to be considered
highly specific for intended use. Application of the
developed method was checked by analyzing the moxi-
floxacin and prednisolone in commercially available
pharmaceutical products. The results are provided in
[Table 7] which showed high percentage recoveries and
low RSD (%) values for both analytes.
Conclusion
A simple, fast and accurate stability indicating RP-HPLC
method is described for simultaneous determination of
moxifloxacin and prednisolone in pharmaceutical for-
mulations. The developed method was validated by
Table 6 Stress Testing Results of Moxifloxacin and Prednisolone
Nature of stress Storage conditions Time (h) Amount of moxifloxacin Amount of prednisolone Extent of
decompositionRemaining±RSD (%) Remaining±RSD (%)
5 M HCl (40°C/75% RH) 16 86.3 ± 3.4 (PPI = 1.0000) 4.8 ± 3.0 (PPI = 1.0000) Substantial
5 M NaOH (22°C/58% RH) 0.67 100.0 ± 2.1 (PPI = 1.0000) 3.4 ± 2.7 (PPI = 1.0000) Substantial
6% H2O2 (40°C/75% RH) 16 96.4 ± 1.5 (PPI = 1.0000) 88.3 ± 1.4 (PPI = 1.0000) Substantial
Thermal (40°C/75% RH) 144 101.3 ± 1.4 (PPI = 1.0000) 100.5 ± 1.9 (PPI = 1.0000) None
(40°C/75% RH) 288 97.5 ± 1.1 (PPI = 1.0000) 97.2 ± 1.5 (PPI = 1.0000) None
Dry Heat (105°C) 7 93.7 ± 1.7 (PPI = 1.0000) 84.1 ± 1.4 (PPI = 1.0000) Substantial
Photolytic Sunlight 1 88.5 ± 1.9 (PPI = 1.0000) 94.5 ± 2.5 (PPI = 1.0000) Substantial
n=Average of 3 determinations, PPI=Peak Purity Index, Chromatographic conditions: mobile phase Methanol: 18 mM phosphate buffer 62:38, v/v, pH 2.8,
Column BDS Hypersil C8 (250 X 4.6, 5 μm), flow rate 1.5 mL min-1, injection volume 20 μL, wavelength 254 nm.
Table 7 Assay results of moxifloxacin and prednisolone in
commercial eye drops





Occumox P Moxifloxacin 5 100.3 ± 0.3
Prednisolone 10 99.0 ± 0.7
Moftrex P Moxifloxacin 5 100.7 ± 0.1
Prednisolone 10 98.9 ±0.7
n=Average of 10 determinations, Chromatographic conditions: mobile phase
Methanol: 18 mM phosphate buffer 62:38, v/v, pH 2.8, Column BDS Hypersil
C8 (250 X 4.6, 5 μm), flow rate 1.5 mL min-1, injection volume 20 μL,
wavelength 254 nm.
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testing its linearity, accuracy, precision, limits of detec-
tion and quantitation and specificity. The method is
simple, fast and is without the use of ion pair or any
derivatization reagent. The method is good enough to
separate the peaks of active pharmaceutical ingredients
(APIs) from the degradation products (produced during
forced degradation studies). So, it is concluded that the
method can be successfully used for any kind of stability
and validation studies.
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